Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice.
The development of immunity to Rhodococcus equi, particularly to a virulence-associated protein (VapA) based antigen preparation, was examined in CD1 and BALB/c mice after intraperitoneal vaccination. Immunization with VapA based antigen without adjuvant markedly enhanced organ clearance in CD1 mice but not in BALB/c mice. Delayed type hypersensitivity response and antibody titres in VapA based antigen immunized BALB/c mice were less than in CD1 mice. By contrast also to CD1 mice, sera from immunized BALB/c mice did not react as strongly with VapA in western blots. Use of adjuvants (aluminium hydroxide, iscoms) interfered markedly with the immunogenic properties of the VapA based antigen, in the case of aluminium hydroxide by apparently driving a Th2 type of response. Unexpectedly, iscom adjuvants also impaired immunity and, despite the highest DTH response, produced a low IgG2a response, suggesting that iscomization of the antigen produced a low interferon gamma and high interleukin 2 response. Passive immunization of BALB/c mice with serum from mice immunized with live virulent strain 103+ resulted in only temporary and slight enhancement of organ clearance, supporting the central importance of cellular immunity to R. equi. Immunization with live virulence plasmid- and VapA-positive R. equi strain 103 resulted in marked liver clearance, in marked DTH response and high antibody titres. By contrast, immunization with live virulence plasmid- and VapA-negative strain 103 resulted in slight but variable enhancement of clearance, but insignificant DTH and antibody. The virulence plasmid, and by implication VapA, was thus shown to be critical in determining a highly effective protection to live organisms.
Prescott
J F
JF
Department of Pathobiology, University of Guelph, Ont., Canada. jprescott@ovcnet.uoguelph.ca
Patterson
M C
MC
Nicholson
V M
VM
Morein
B
B
Yager
J A
JA
D000193:Actinomycetales Infections / Q000276:immunology* / Q000517:prevention & control / Q000662:veterinary; D000704:Analysis of Variance; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D001428:Bacterial Vaccines; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006734:Horse Diseases; D006736:Horses; D006968:Hypersensitivity, Delayed; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification; D008074:Lipoproteins / Q000276:immunology*; D008099:Liver / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D018410:Pneumonia, Bacterial / Q000276:immunology* / Q000517:prevention & control / Q000662:veterinary; D016929:Rhodococcus equi / Q000276:immunology* / Q000302:isolation & purification; D013045:Species Specificity; D013154:Spleen / Q000382:microbiology; D037521:Virulence Factors
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D008074:Lipoproteins; D037521:Virulence Factors